The Leukemia & Lymphoma Society (LLS) and Memgen jointly announced an agreement today to collaborate on a new Phase I clinical trial. The trial will use Memgen's ISF35, an active immunotherapy approach for treating chronic lymphocytic leukemia (CLL)....
Read More...
[Source: Society News]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment